Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Chardan Capital boosted their price target on Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, August 4th. BMO Capital Markets boosted their price target on Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the stock a "market perform" rating in a research report on Thursday, August 4th. William Blair initiated coverage on Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They set an "outperform" rating for the company. Guggenheim cut Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating in a research report on Monday, June 27th. Finally, Cantor Fitzgerald assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, July 12th. They issued a "neutral" rating and a $175.00 target price for the company. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $227.29.

Alnylam Pharmaceuticals Trading Up 1.9 %

ALNY traded up $4.46 during mid-day trading on Friday, hitting $233.85. 619,833 shares of the stock were exchanged, compared to its average volume of 1,283,372. The firm's fifty day moving average is $155.53 and its two-hundred day moving average is $151.22. Alnylam Pharmaceuticals has a 1-year low of $117.58 and a 1-year high of $236.80. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 3.85. The company has a market cap of $28.07 billion, a PE ratio of -28.62 and a beta of 0.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The firm had revenue of $224.80 million for the quarter, compared to analyst estimates of $256.06 million. During the same period in the previous year, the company posted ($1.61) EPS. Alnylam Pharmaceuticals's revenue was up 1.9% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals will post -8.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,841 shares of the company's stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $218.16, for a total transaction of $401,632.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 5,349 shares of company stock valued at $1,033,073. Corporate insiders own 1.40% of the company's stock.